Anti-isoAsp7 amyloid β (Aβ) antibodies and uses thereof

US11703511B2 · kind B2 · utility

Assignee

• Fraunhofer-Gesellschaft zur förderung der angewandten Forschung e.V. · DE

Inventors

• Anke Piechotta · Bodenwerder, DE
• Kathrin Gnoth · Halle (Saale), DE
• Holger Cynis · Dohnsen, DE
• Jens-Ulrich Rahfeld · Lieskau, DE
• Stephan Schilling · Halle (Saale), DE
• Hans-Ulrich Demuth · Halle (Saale), DE

Key dates

• Filing date: Jul 17, 2018
• Grant date: Jul 18, 2023
• Expiry date: Feb 25, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention can be included in the field of medicine. Specifically, the present invention provides antibodies and antigen-binding fragments thereof which can bind isoAsp7 amyloid β (Aβ) and a pharmaceutical composition comprising the antibodies or antigen-binding fragments thereof. IsoAsp7 Aβ can be found in plaques of Alzheimer's patients and is thus a suitable target for the treatment and/or prevention of Aβ-related diseases such as Alzheimer's disease. Thus, the antibodies, antigen-binding fragments thereof and the pharmaceutical composition comprising either can be used to treat and/or prevent neurodegenerative diseases. Further, the present invention provides hybridoma cell lines, the use of the antibodies or antigen-binding fragments thereof for the diagnosis and/or prognosis of a neurodegenerative disease and a method for detecting isoAsp7 Aβ in an isolated sample.